Lead Product(s) : JADE-001
Therapeutic Area : Nephrology
Study Phase : Preclinical
Sponsor : Jade Biosciences
Deal Size : Undisclosed
Deal Type : Merger
Aerovate Shareholders Approve Merger with Jade Biosciences and All Proposals
Details : The combined company will focus on advancing Jade’s portfolio of novel biologics, including JADE-001, a promising anti-APRIL monoclonal antibody for IgA nephropathy.
Product Name : JADE-001
Product Type : Antibody
Upfront Cash : Undisclosed
April 21, 2025
Lead Product(s) : JADE-001
Therapeutic Area : Nephrology
Highest Development Status : Preclinical
Sponsor : Jade Biosciences
Deal Size : Undisclosed
Deal Type : Merger
Lead Product(s) : TNX-1500,Undisclosed
Therapeutic Area : Nephrology
Study Phase : Preclinical
Sponsor : Makana Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
Tonix, Makana Partner On Anti-CD40L Antibody and Xenotransplantation
Details : Tonix and Makana will study Tonix’s anti-CD40L monoclonal antibody candidate, TNX-1500, in combination with Makana’s human-compatible organs and cells for the treatment of organ failure.
Product Name : TNX-1500
Product Type : Antibody
Upfront Cash : Undisclosed
April 09, 2025
Lead Product(s) : TNX-1500,Undisclosed
Therapeutic Area : Nephrology
Highest Development Status : Preclinical
Sponsor : Makana Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Bi-Sialidase,Rituximab
Therapeutic Area : Nephrology
Study Phase : Preclinical
Sponsor : Henlius
Deal Size : $95.3 million
Deal Type : Licensing Agreement
Palleon and Henlius Partner On Glycan Editing for Autoimmune Disease Treatment
Details : Henlius has obtained an exclusive license in China for E-602 and will advance its development in combination with Hanlikang for the treatment of autoimmune diseases, including lupus nephritis.
Product Name : E-602
Product Type : Protein
Upfront Cash : Undisclosed
December 19, 2024
Lead Product(s) : Bi-Sialidase,Rituximab
Therapeutic Area : Nephrology
Highest Development Status : Preclinical
Sponsor : Henlius
Deal Size : $95.3 million
Deal Type : Licensing Agreement
Lead Product(s) : JADE-001
Therapeutic Area : Nephrology
Study Phase : Preclinical
Sponsor : Jade Biosciences
Deal Size : Undisclosed
Deal Type : Merger
Aerovate Therapeutics and Jade Biosciences Announce Merger Agreement
Details : The combined company will focus on advancing Jade’s portfolio of novel biologics, including JADE-001, a promising anti-APRIL monoclonal antibody for IgA nephropathy.
Product Name : JADE-001
Product Type : Other Large Molecule
Upfront Cash : Undisclosed
October 31, 2024
Lead Product(s) : JADE-001
Therapeutic Area : Nephrology
Highest Development Status : Preclinical
Sponsor : Jade Biosciences
Deal Size : Undisclosed
Deal Type : Merger
Lead Product(s) : Undisclosed
Therapeutic Area : Nephrology
Study Phase : Preclinical
Sponsor : Atlas Venture
Deal Size : $100.0 million
Deal Type : Series A Financing
Judo Bio Debuts with $100M and To Take RNA Drugs to The Kidney
Details : The proceeds from the financing will be used to advance the lead ligand-siRNA conjugate to the clinic and to further build the proprietary STRIKE platform for the treatment of kidney diseases.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
July 10, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Nephrology
Highest Development Status : Preclinical
Sponsor : Atlas Venture
Deal Size : $100.0 million
Deal Type : Series A Financing
Lead Product(s) : Zegocractin
Therapeutic Area : Nephrology
Study Phase : Preclinical
Sponsor : Deerfield Management
Deal Size : $55.0 million
Deal Type : Private Placement
CalciMedica Announces Private Placement of up to Approximately $55 Million
Details : The net proceeds will be used for the clinical development of the Auxora (zegocractin), which is a small molecule CRAC channel inhibitor and are also planning for Phase 2 for acute kidney injury.
Product Name : Auxora
Product Type : Other Small Molecule
Upfront Cash : $20.4 million
January 22, 2024
Lead Product(s) : Zegocractin
Therapeutic Area : Nephrology
Highest Development Status : Preclinical
Sponsor : Deerfield Management
Deal Size : $55.0 million
Deal Type : Private Placement
Lead Product(s) : Tegoprubart
Therapeutic Area : Nephrology
Study Phase : Preclinical
Sponsor : Eledon Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Collaboration
Details : AT-1501 (tegoprubart) is an investigational, humanized IgG1 anti-CD40L antibody with high affinity for the CD40 ligand. CD40L plays a pivotal role in immune system activation by mediating both antibody and cellular immune responses.
Product Name : AT-1501
Product Type : Antibody
Upfront Cash : Undisclosed
September 01, 2023
Lead Product(s) : Tegoprubart
Therapeutic Area : Nephrology
Highest Development Status : Preclinical
Sponsor : Eledon Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : REVTx-300
Therapeutic Area : Nephrology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Revelation Biosciences Inc. Announces Preclinical Biomarker Data Supporting Activity of REVTx-300
Details : REVTx-300 is a inhibitor of TGF-b, formulated for systemic administration of PHAD and is being developed as a potential therapy for CKD, AKI, myocarditis and NASH.
Product Name : REVTx-300
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 02, 2023
Lead Product(s) : REVTx-300
Therapeutic Area : Nephrology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Nephrology
Study Phase : Preclinical
Sponsor : Guangdong Academy of Medical Sciences
Deal Size : Undisclosed
Deal Type : Agreement
Details : The agreement is for the comprehensive strategic cooperation with Guangdong Academy of Medical Sciences in renal disease research, scientific innovation and translational studies.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
March 23, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Nephrology
Highest Development Status : Preclinical
Sponsor : Guangdong Academy of Medical Sciences
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Undisclosed
Therapeutic Area : Nephrology
Study Phase : Preclinical
Sponsor : Selecta Biosciences
Deal Size : $1.6 million
Deal Type : Licensing Agreement
Details : The selection of a next generation Immunoglobulin A (IgA) protease from IGAN Biosciences for its IgA nephropathy (IgAN) program, will lead Selecta Biosciences to pay IGAN Biosciences.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
December 14, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Nephrology
Highest Development Status : Preclinical
Sponsor : Selecta Biosciences
Deal Size : $1.6 million
Deal Type : Licensing Agreement